1. Genetic interference exerted by Salmonella-delivered CRISPR/Cas9 significantly reduces the pathological burden caused by Marek’s disease virus in chickens
- Author
-
John Hwa Lee, Chamith Hewawaduge, and Amal Senevirathne
- Subjects
Salmonella ,qRT–PCR ,Veterinary medicine ,Virulence ,Gene delivery ,medicine.disease_cause ,Virus ,Plasmid ,SF600-1100 ,medicine ,Marek Disease ,CRISPR ,Animals ,Herpesvirus 2, Gallid ,CRISPR/Cas9 ,Poultry Diseases ,Marek's disease ,genomic interference ,General Veterinary ,biology ,Cas9 ,biology.organism_classification ,Virology ,Leukocytes, Mononuclear ,Female ,virus-induced cancer ,CRISPR-Cas Systems ,Chickens ,Research Article ,Plasmids - Abstract
Efficient in vivo delivery of a CRISPR/Cas9 plasmid is of paramount importance for effective therapy. Here, we investigated the usability of Salmonella as a plasmid carrier for in vivo therapy against virus-induced cancer using Marek’s disease virus (MDV) as a model for study in chickens. A green fluorescent protein-expressing CRISPR/Cas9 plasmid encoding the virulence gene pp38 was constructed against Marek’s disease virus. Therapeutic plasmids were transformed into Salmonella carrying lon and sifA gene deletions. The animals in 5 groups were intraperitoneally inoculated with phosphate-buffered saline, vector control, or Salmonella before or after MDV infection, or left uninfected as a naïve control. Therapeutic effectiveness was evaluated by observing disease outcomes and the viral copy number in peripheral blood mononuclear cells. The efficacy of plasmid delivery by Salmonella was 13 ± 1.7% in the spleen and 8.0 ± 1.8% in the liver on the 6th day post-infection. The Salmonella-treated groups showed significant resistance to MDV infection. The maximum effect was observed in the group treated with Salmonella before MDV infection. None of the chickens fully recovered; however, the results suggested that timely delivery of Salmonella could be effective for in vivo CRISPR/Cas9-mediated genetic interference against highly pathogenic MDV. The use of Salmonella in CRISPR systems provides a simpler and more efficient platform for in vivo therapy with CRISPR than the use of conventional in vivo gene delivery methods and warrants further development.
- Published
- 2021